453 related articles for article (PubMed ID: 19092334)
1. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.
Schneider PM; Metzger R; Schaefer H; Baumgarten F; Vallbohmer D; Brabender J; Wolfgarten E; Bollschweiler E; Baldus SE; Dienes HP; Hoelscher AH
Ann Surg; 2008 Dec; 248(6):902-8. PubMed ID: 19092334
[TBL] [Abstract][Full Text] [Related]
2. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
3. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
[TBL] [Abstract][Full Text] [Related]
4. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
[TBL] [Abstract][Full Text] [Related]
5. Closing the loop around esophagectomy after neoadjuvant therapy.
Demeester SR
Ann Surg; 2009 Sep; 250(3):500; author reply 500. PubMed ID: 19730188
[No Abstract] [Full Text] [Related]
6. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
7. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
[TBL] [Abstract][Full Text] [Related]
8. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
9. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
10. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
11. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
Mariette C; Piessen G; Briez N; Triboulet JP
Ann Surg; 2008 Feb; 247(2):365-71. PubMed ID: 18216546
[TBL] [Abstract][Full Text] [Related]
12. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.
Kesler KA; Helft PR; Werner EA; Jain NP; Brooks JA; DeWitt JM; Leblanc JK; Fineberg NS; Einhorn LH; Brown JW
Ann Thorac Surg; 2005 Apr; 79(4):1116-21. PubMed ID: 15797035
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
16. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
Miyata H; Yoshioka A; Yamasaki M; Nushijima Y; Takiguchi S; Fujiwara Y; Nishida T; Mano M; Mori M; Doki Y
Cancer; 2009 Jul; 115(14):3324-34. PubMed ID: 19452547
[TBL] [Abstract][Full Text] [Related]
17. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma.
Korst RJ; Kansler AL; Port JL; Lee PC; Kerem Y; Altorki NK
Ann Thorac Surg; 2006 Aug; 82(2):480-4; discussion 484-5. PubMed ID: 16863749
[TBL] [Abstract][Full Text] [Related]
18. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
19. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
Hsu FM; Lin CC; Lee JM; Chang YL; Hsu CH; Tsai YC; Lee YC; Cheng JC
J Surg Oncol; 2008 Jul; 98(1):34-41. PubMed ID: 18449912
[TBL] [Abstract][Full Text] [Related]
20. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]